“Banning Coldrif Syrup After 21 Child Deaths: India’s Pharmaceutical Safety Crisis Deepens”

In a devastating public health incident in central India, the death toll from a tainted cough syrup has risen to 21 children in Madhya Pradesh as of early October 2025. The deaths, occurring over several weeks in districts including Chhindwara, Betul, and Pandhurna, were attributed to acute kidney failure following consumption of a cough syrup found to contain a dangerously high concentration of diethylene glycol (DEG)—an industrial chemical toxic to humans. This tragedy has sparked widespread governmental and public scrutiny of pharmaceutical safety standards in India’s thriving drug market.

Key Findings and Developments

The contaminated cough syrup, branded Coldrif and produced by Sresan Pharmaceuticals based in Tamil Nadu, was detected to contain 48.6% diethylene glycol, far exceeding the permissible limit of 0.1% set by drug safety standards. Diethylene glycol is a solvent primarily used in industrial applications such as antifreeze and plastics and is highly toxic when ingested, even in small amounts, leading to rapid kidney failure due to its metabolism into harmful compounds that damage renal tissue.

Initial deaths were reported in Chhindwara, where 18 children succumbed to kidney failure after reportedly consuming Coldrif cough syrup prescribed for respiratory symptoms. Subsequent fatalities in Betul and Pandhurna districts have raised the overall toll to 21, with several children in critical condition still under intensive care. Investigations have revealed manufacturing violations at the Sresan Pharmaceuticals facility, and the company’s owner has been absconding since early October.

Governmental responses have included a total ban on the sale and distribution of Coldrif syrup across multiple states — Madhya Pradesh, Kerala, and Tamil Nadu — as well as bans on other cough syrups with strikingly similar toxic contamination detected in Gujarat. The Madhya Pradesh government has announced significant compensation for affected families and committed to covering the full treatment costs of surviving children.

Expert Commentary

 “Diethylene glycol poisoning leads to acute tubular necrosis and rapid kidney failure in young children due to their smaller body mass and developing organs. Early supportive care can improve outcomes, but prevention by ensuring drug safety is paramount.” Dr. Mehta underscores the particular vulnerability of children under five to toxic exposures in pharmaceuticals.

Pharmaceutical safety expert Prof. Raghav Singh of the All India Institute of Medical Sciences notes, “This tragedy highlights systemic gaps in drug quality control oversight in India, where fragmented regulatory frameworks and a vast number of small manufacturers create compliance challenges. There is an urgent need for strengthened regulatory enforcement and greater transparency to protect public health.”

Context and Background

India’s pharmaceutical industry is a major global supplier of generic drugs and over-the-counter medicines, including cough syrups. However, low-cost production pressures and insufficient regulation have previously led to episodes of medicine contamination. Similar incidents involving diethylene glycol poisoning from cough syrups have tragically occurred in other regions, including a highly publicized outbreak in Gambia in 2022.

The regulatory standards require pharmaceutical-grade solvents such as propylene glycol to be used in syrup formulations; substitution with cheaper, toxic industrial solvents like DEG poses grave risks. Despite existing standards, enforcement lapses and inadequate testing protocols enable contaminated products to reach consumers, particularly in rural and underserved areas.

Implications for Public Health

This crisis underlines the critical need for robust pharmaceutical quality control systems and routine surveillance to prevent medication-related poisoning. Public health authorities must prioritize stringent inspection of manufacturing processes, especially for pediatric medicines, and ensure prompt recalls of contaminated batches.

For consumers and caregivers, vigilance regarding medication sourcing and consulting qualified healthcare providers before administering over-the-counter syrups is essential. Medical professionals should be alert to symptoms of toxic ingestion, such as decreased urine output, vomiting, and lethargy in children, for early diagnosis and intervention.

Potential Limitations and Counterarguments

While the cluster of deaths is strongly linked to DEG contamination, critics point to delays in initial governmental acknowledgment, which may have contributed to continued exposure. The accountability of not only pharmaceutical manufacturers but also prescribing physicians and regulatory bodies is under debate. Some experts caution that while regulatory reforms are necessary, focusing solely on contamination incidents without addressing broader systemic healthcare access issues limits long-term protections.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. “Cough syrup tragedy: Death toll mounts to 21 as children die in 2 more MP districts, CM Yadav admits lapses,” Times of India, October 8, 2025.